{
  "paper_metadata": {
    "pmid": "32773395",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.148G>A",
      "protein_notation": "p.Val50Met",
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 130,
        "demographics": "not specified",
        "phenotype": "TTR-related peripheral neuropathy"
      },
      "penetrance_data": {
        "total_carriers_observed": 130,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "Patisiran treatment showed improvement in neuropathy in patients carrying the c.148G>A variant.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": null,
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The variant is common among patients with TTR-related neuropathy.",
      "key_quotes": [
        "The third study (APOLLO) examined the effect of patisiran, a double-stranded synthetic ribonucleic acid molecule (RNAi) that targets mutant and wild type TTR, after 18 months treatment in patients carrying the c.148G>A (p.Val50Met) (\u223c50% of patients) or other TTR mutations."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data for the TTR gene was extracted successfully."
  }
}